Scientists have identified a new mechanism of bacterial pathogenesis. The results of the research project, partly funded by the Academy of Finland, have been published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Bacteria that cause chronic infections have an amazing but yet poorly known ability to subvert immune response, live and produce offspring, enter and wake up from a dormant phase to cause, in some instances, deadly complications.
Bartonella bacteria cause chronic infections in mammals (incl. humans), and are typically transmitted to new hosts mainly by arthropod vectors such as fleas, lice and ticks, but also via direct tissue trauma (e.g. cat scratches).
One very notable feature of these bacteria is their ability to cause vasoproliferative tumours that resemble Kaposi's sarcoma in patients suffering from immunodeficiency (e.g. AIDS, aggressive cancer treatments, organ transplantation). If left untreated, these foci of inflammation maintain a chronic infection and contribute to transmitting bacteria to new hosts.
In his research, biologist Arto Pulliainen of the University of Turku has demonstrated that Bartonella henselae injects a protein called BepA into vascular endothelial cells and that this protein manipulates cAMP-mediated cell signalling using a previously unknown mechanism.
BepA directly binds the host cell adenylyl cyclase, which is an enzyme responsible for the production of cAMP. However, the binding of BepA to the adenylyl cyclase does not activate cAMP production per se, but the adenylyl cyclase rather becomes more sensitive to its natural activator, stimulatory G-protein (Gs). The cellular concentration of cAMP increases and prevents the death of the host cell. BepA significantly prolongs the lifespan of the host cell and partly contributes to the formation of vasoproliferative tumours.
Several bacterial species are known to manipulate host cell functions via cAMP-mediated cell signalling. The symptoms are typically very strong and may even be deadly. The best-known example is Vibrio cholerae and its cholera toxin, which modifies Gs into a permanently adenylyl cyclase-stimulating form. BepA, in turn, manipulates host cell signalling in a subtle sophisticated manner, which is ideal for chronic persistence of Bartonella henselae in the infected vascular endothelium.
The research has been carried out at the Universities of Basel and Turku.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.